Lenvima (lenvatinib) / Eisai, Merck (MSD), Knight Therap - LARVOL DELTA

Neoadjuvant Radiotherapy Combined with Lenvatinib and Sintilimab in Patients with Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: An Open-Label, Single-Arm, Multicenter, Prospective Phase I Clinical Trial (ASTRO 2026) - P1 | "Neoadjuvant radiotherapy combined with lenvatinib and sintilimab can bring a high tumor response rate in patients with resectable hepatocellular carcinoma with portal vein tumor thrombu with a favorable safety profiles. PVTT demonstrates higher response rate than primary HCC lesions. Discrepancies between imaging and pathological responses highlight the need for improved predictive biomarkers."

Clinical • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor

Organ-preservation value of sequential PD-1 inhibitors followed by selective sintilimab/IBI310/lenvatinib in non-metastatic MSI-H/dMMR gastric and colon cancer. (ESMO 2026) - No abstract available

dMMR • Metastases • MSI-H • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Response of HER2 positive gallbladder adenocarcinoma to trastuzumab emtansine (T-DM1): a case report and literature review. (PubMed, Front Oncol) - "This report describes the case of a 46-year-old middle-aged man with human epidermal growth factor receptor 2 (HER2)-positive metastatic gallbladder adenocarcinoma who was treated preoperatively with two cycles of gemcitabine, oxaliplatin, lenvatinib, and sintilimab; the best objective response was stable disease. After 2 cycles, the lesion was reduced in size and surgical resection was achieved, and the patient underwent radical cholecystectomy for gallbladder cancer (GBC), with a disease-free survival of 13 months after surgery. This case demonstrates the efficacy of trastuzumab emtansine in the treatment of locally advanced GBC, suggesting that HER2 mutation is important in GBC and that anti-HER2 drug therapy may be an option for the systemic treatment of GBC."

Journal • Biliary Cancer • Biliary Tract Cancer • Gallbladder Cancer • Oncology • Solid Tumor • HER-2

Impact of Neoadjuvant TKI Therapy on Tumor Reduction and Resectability in Locally Advanced Thyroid Carcinoma (ETA 2026) - "Therapies included selective (dabrafenib/trametinib, entrectinib, larotrectinib, selpercatinib) and multikinase inhibitors (lenvatinib, cabozantinib, vandetanib)... Neoadjuvant TKI therapy demonstrated promising results in locally advanced thyroid carcinoma, achieving high disease control rates and enabling surgical resection in over one-third of cases. Outcomes were comparable between selective and multikinase TKIs, and meaningful responses were observed across histological subtypes, although survival remained significantly longer in differentiated tumors. These findings, representing one of the largest single-center cohorts, reinforce the growing role of neoadjuvant therapy in multidisciplinary management of advanced thyroid cancer."

Clinical • Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK

Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial. (PubMed, Med) - "Sintilimab, lenvatinib, and TACE-HAIC demonstrated favorable conversion-to-resection rates and acceptable TRAEs in uHCC."

Journal • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Shunda Du

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of TACE versus HAIC combined with sintilimab and lenvatinib in patients with intermediate‑advanced hepatocellular carcinoma: a retrospective cohort study (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Affiliated Qingyuan Hospital, Guangzhou Medical University (Qingyuan People's Hospital); Affiliated Qingyuan Hospital, Guangzhou Medical University (Q

New trial • Cardiovascular • Fatigue • Hematological Disorders • Hepatocellular Cancer • Liver Cancer • Oncology • Pain • Solid Tumor • Thrombosis

Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial. (ASCO 2026) - P1 | "Neoadjuvant radiotherapy combined with lenvatinib and sintilimab can bring a high tumor response rate in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus with a favorable safety profiles. PVTT demonstrates higher response rate than primary HCC lesions. Discrepancies between imaging and pathological responses highlight the need for improved predictive biomarkers."

Clinical • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis

From Cure to Recurrence: Very Early Metastatic Hepatocellular Carcinoma After Living Donor Liver Transplantation (ACG 2026) - "Sequential TKI therapy with lenvatinib and cabozantinib was limited by progression and toxicity. With AFP now >500 ng/mL, ramucirumab or regorafenib are under consideration...(B) Pankeratin (panCK) immunostain highlighting tumor cells. Original magnification Ã500."

Metastases • Cardiovascular • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Portal Hypertension • Solid Tumor • Transplantation

Anti-angiogenic therapy in thymic carcinoma: a narrative review of current evidence and emerging combinations. (PubMed, Mediastinum) - "In the first-line setting, VEGFR-2 inhibition with ramucirumab combined with platinum-based chemotherapy has achieved encouraging response rates and prolonged progression-free survival (PFS), though findings require cautious interpretation given small sample sizes and early termination of the trials without phase III confirmation. Multikinase inhibitors, such as sunitinib and lenvatinib, provide durable disease control in previously treated patients, with benefit closely linked to maintaining adequate dose intensity...The evidence base nevertheless rests on small phase II studies without confirmatory phase III data or broad regulatory approval. Future progress will depend on optimizing treatment sequencing, improving toxicity management, and advancing biomarker-driven patient selection through collaborative, multi-institutional efforts."

IO biomarker • Journal • Review • Oncology • Solid Tumor • Thymic Carcinoma • Thymic Epithelial Tumor • Thymus Cancer

Yttrium-90 SIRT followed by lenvatinib plus sintilimab for unresectable intermediate-to-advanced hepatocellular carcinoma: Phase II SIRLENS-90 trial. (ASCO 2026) - P2 | "Yttrium-90 SIRT followed by lenvatinib plus sintilimab demonstrated encouraging activity with manageable toxicity in unresectable intermediate-to-advanced HCC. The cytokine-integrated baseline risk score is hypothesis-generating and warrants external validation."

IO biomarker • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor • CXCL11 • IL5

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial. (PubMed, Signal Transduct Target Ther) - P2 | "Among those who achieved successful conversion, subsequent curative surgery demonstrated not only a favorable safety profile but also significant survival benefits. Trial registration number: ChiCTR1900023914."

Journal • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, J Gastrointest Oncol) - "For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone...For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS...For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation."

Checkpoint inhibition • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Marked response to dabrafenib plus trametinib in a patient with BRAF V600E-mutant pancreatic hepatoid carcinoma: a case report and systematic analysis of 57 cases. (PubMed, Front Oncol) - "After two cycles of pembrolizumab-based first-line therapy combined with paclitaxel, S-1, and lenvatinib, AFP continued to increase and imaging showed rapid tumor enlargement, consistent with immune checkpoint inhibitor-related hyperprogressive disease...Subsequent addition of cetuximab, replacement of the MEK inhibitor, and dose escalation of targeted therapy did not restore sustained systemic disease control, although local disease remained manageable with subsequent treatment adjustments...After resistance to targeted therapy, local radiotherapy may serve as an important strategy for controlling oligoresidual and oligometastatic lesions. Together with the literature review, this case supports early comprehensive molecular profiling and individualized multidisciplinary management for advanced PHC."

IO biomarker • Journal • Tumor mutational burden • Hepatocellular Cancer • Hepatology • Liver Failure • Oncology • Pain • Pancreatic Cancer • Solid Tumor • Thrombosis • AFP • BRAF • MDM2 • MGMT • MYC • PD-L1 • TMB

A phase II trial of liposomal irinotecan plus sintilimab and lenvatinib for second-line advanced gastric/GEJ adenocarcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Gastroesophageal Junction Adenocarcinoma • Oncology

Stereotactic body radiotherapy plus cadonilimab and lenvatinib as conversion therapy for potentially resectable hepatocellular carcinoma (UniRTX): A phase II study. (ASCO 2026) - P=N/A | "SBRT plus cadonilimab and lenvatinib showed encouraging efficacy and manageable toxicity as a conversion strategy for potentially resectable HCC."

P2 data • Gastrointestinal Disorder • Hematological Disorders • Hepatocellular Cancer • Hepatology • Leukopenia • Neutropenia • Oncology • Solid Tumor • PD-1

Durable Antitumor Activity of Cadonilimab Plus Lenvatinib After Frontline IO+TKI Failure in Advanced Clear Cell RCC: Updated Phase II CLEAR-IT Results (ESMO 2026) - No abstract available

Metastases • P2 data • Clear Cell Renal Cell Carcinoma • Oncology • Renal Cell Carcinoma

Association between gut microbiota characteristics and therapeutic efficacy of multimodal combination therapy in hepatocellular carcinoma with portal vein tumor thrombus: a secondary analysis of a prospective phase II trial. (PubMed, Front Immunol) - P1/2 | "Although SBRT combined with cadonilimab and lenvatinib has shown encouraging antitumor activity in a prior prospective phase II trial, marked interpatient heterogeneity remains...Extibacter showed an exploratory non-response-associated signal that requires validation in larger independent studies. ClinicalTrials.gov, identifier NCT06040177."

Journal • P2 data • Hepatocellular Cancer • Immunology • Oncology • Solid Tumor • Thrombosis

CCGLC-011: HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Tongji Hospital | Active, not recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: a multicenter, single-arm, phase II trial (SGO 2025) - No abstract available

Clinical • Metastases • P2 data • Endometrial Cancer • Oncology • Solid Tumor

Perioperative cadonilimab plus lenvatinib for resectable locally advanced clear cell renal cell carcinoma: a prospective, single-center, single-arm, exploratory phase II trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-metastatic Hepatocellular Carcinoma: Long-term OS Results (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Oncology • Renal Cell Carcinoma